OncoMed Pharmaceuticals Files For IPO
Redwood City-based OncoMed Pharmaceuticals filed for an IPO Friday, saying that it is looking to raised up to $115M on the NASDAQ Global Market as OMED. The firm's IPO is being underwritten by Jefferies, Leerink Swann,
Piper Jaffray, and BMO Capital Markets. OncoMed is a developer of monoclonal antibody therapeutics targeting cancer stem cells. The firm is backed by U.S. Venture Partners, Latterrel Venture Partners, GlaxoSmithKline, The Vertical Group, Morgenthaler Partners, Phase4 Ventures, Delphi Ventures, Adams Street Partners, along with others.
posted on Friday, May 11, 2012
Related companies:
OncoMed Pharmaceuticals
Related stories:
> OncoMed Pharmaceuticals Boosts Shares In IPO Offering
> OncoMed Gets $94M
> TriplePoint Capital Raises $1 Billion Venture Debt Fund
> Anacor Pharmaceuticals Files For IPO
> MAP Pharmaceuticals Files For IPO
silicontap.com Home